In the news | 6th January 2014
Banking on biologics
American Laboratory
January 2014
Biologics means big bucks and big rewards. The pharma industry is keen to capitalize on this success as revenues are tipped to reach over $407 billion by 2018. By this time, more than 50% of the top 100 selling drugs will be biologics.
More news
How to get more insight and value out of your Electronic Batch Record data with PIMS
Discover how PIMS can work synergistically with your existing Electronic Batch Record (EBR) software and why PIMS is a great alternative.
New process definition capabilities in PIMS further enhance quality assurance and “right-first-time” initiatives for pharma manufacturers
New process definition capabilities in PIMS 5.1, further enhance quality assurance and “right-first-time” initiatives for pharma manufacturers.
Tradeshow | European BioAnalysis Forum | Nov 2023
Speak to our experts to learn how an innovative approach to transform your bioanalytical operations and to improve data quality, productivity and compliance, according to industry standards such as ICH M10 standards
Software validation keeps GxP systems current and speeds up time-to-market
Requirements to maintain a GxP environment means researchers must conduct software validation on any updated software so it continues to meet users’ needs.